GlassScriptPhysician profile
Desire Ingabire
NPI 1700449030
$7,589.03
in general payments reported to CMS, 2019-2025
30 companies · $548 in 2025
The $548 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,153 · 2022: $1,458 · 2023: $2,686 · 2024: $1,744 · 2025: $548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,977.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,184.77 | 2021-2025 | Rexulti, Abilify Mycite, Abilify Asimtufii |
| Alkermes, INC. | $910.51 | 2021-2025 | Aristada, Lybalvi |
| Abbvie INC. | $886.94 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $495.34 | 2021-2024 | Caplyta |
| Corium, LLC | $452.87 | 2022-2025 | Azstarys |
| Lundbeck LLC | $395.02 | 2021-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $384.18 | 2023-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $363.79 | 2021-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $333.78 | 2022-2025 | Auvelity |
| Neos Therapeutics, LP | $289.07 | 2021-2025 | Adzenys Xr-Odt |
| Tris Pharma INC | $272.99 | 2022-2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $261.59 | 2022-2024 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $227.24 | 2021-2024 | Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $220.13 | 2022-2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $153.48 | 2021-2024 | Trintellix |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $140.71 | 2023-2024 | Spravato |
| Noven Therapeutics, LLC | $100.90 | 2023-2025 | Xelstrym, Secuado |
| Bausch Health US, LLC | $100.65 | 2022-2025 | Aplenzin |
| Vertical Pharmaceuticals, LLC | $78.45 | 2024-2025 | Relexxii |
| Merck Sharp & Dohme LLC | $62.57 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $50.48 | 2021 | |
| Vanda Pharmaceuticals INC. | $49.34 | 2021-2025 | Fanapt |
| Arbor Pharmaceuticals, INC. | $34.77 | 2021 | |
| Avanir Pharmaceuticals, INC. | $33.87 | 2021 | |
| Collegium Pharmaceutical, INC. | $23.39 | 2025 | Jornay Pm |
| Avion Pharmaceuticals | $19.94 | 2023 | Methylphenidate Hydrochloride |
| Alfasigma USA, INC. | $18.35 | 2021 | |
| Eisai INC. | $17.08 | 2021 | |
| Adlon Therapeutics L.P. | $13.68 | 2021 | |
| Owp Pharmaceuticals, INC. | $13.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Desire Ingabire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.